# Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria

> **NCT02411994** · PHASE3 · COMPLETED · sponsor: **Royal Tropical Institute** · enrollment: 197 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Pyronaridine-artesunate
- **DRUG:** Artemether-lumefantrine combination

## Key facts

- **NCT ID:** NCT02411994
- **Lead sponsor:** Royal Tropical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2017-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02411994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02411994, "Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02411994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*